CVRx (NASDAQ:CVRX) Price Target Raised to $11.00 at Canaccord Genuity Group

CVRx (NASDAQ:CVRX) had its target price boosted by Canaccord Genuity Group from $9.00 to $11.00 in a research note released on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities analysts also recently weighed in on the company. Cantor Fitzgerald boosted their price target on CVRx from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday. Weiss Ratings restated a “sell (e+)” rating on shares of CVRx in a research note on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, CVRx currently has an average rating of “Moderate Buy” and a consensus price target of $13.17.

CVRx Stock Down 3.4%

CVRX stock traded down $0.34 during midday trading on Thursday, hitting $9.71. The company’s stock had a trading volume of 370,914 shares, compared to its average volume of 292,047. The company’s fifty day moving average price is $8.70 and its 200 day moving average price is $7.52. CVRx has a twelve month low of $4.30 and a twelve month high of $18.55. The company has a debt-to-equity ratio of 0.85, a current ratio of 11.99 and a quick ratio of 10.78. The stock has a market capitalization of $253.94 million, a P/E ratio of -4.62 and a beta of 1.28.

CVRx (NASDAQ:CVRX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.01. CVRx had a negative return on equity of 79.31% and a negative net margin of 95.61%.The firm had revenue of $14.69 million during the quarter, compared to the consensus estimate of $14.16 million. CVRx has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts predict that CVRx will post -1.91 EPS for the current year.

Institutional Investors Weigh In On CVRx

Several institutional investors and hedge funds have recently bought and sold shares of the company. Larson Financial Group LLC bought a new stake in shares of CVRx during the 1st quarter worth approximately $28,000. Mount Lucas Management LP bought a new stake in shares of CVRx during the 2nd quarter worth $30,000. Whittier Trust Co. acquired a new stake in CVRx in the first quarter valued at about $73,000. AlphaQuest LLC grew its position in CVRx by 725.4% in the first quarter. AlphaQuest LLC now owns 6,108 shares of the company’s stock valued at $75,000 after acquiring an additional 5,368 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in CVRx during the second quarter worth about $59,000. Institutional investors own 75.27% of the company’s stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.